These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 12197842)

  • 1. Premature discontinuation of interferon plus ribavirin for adverse effects: a multicentre survey in 'real world' patients with chronic hepatitis C.
    Gaeta GB; Precone DF; Felaco FM; Bruno R; Spadaro A; Stornaiuolo G; Stanzione M; Ascione T; De Sena R; Campanone A; Filice G; Piccinino F
    Aliment Pharmacol Ther; 2002 Sep; 16(9):1633-9. PubMed ID: 12197842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive factors for adverse dermatological events during pegylated/interferon alpha and ribavirin treatment for hepatitis C.
    Li Z; Zhang Y; An J; Feng Y; Deng H; Xiao S; Ji F
    J Clin Virol; 2014 Jul; 60(3):190-5. PubMed ID: 24830933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT).
    Poynard T; Marcellin P; Lee SS; Niederau C; Minuk GS; Ideo G; Bain V; Heathcote J; Zeuzem S; Trepo C; Albrecht J
    Lancet; 1998 Oct; 352(9138):1426-32. PubMed ID: 9807989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ribavirin with or without alpha interferon versus no intervention, placebo or alpha interferon for chronic hepatitis C.
    Kjaergard LL; Krogsgaard K; Gluud C
    Cochrane Database Syst Rev; 2002; (1):CD002234. PubMed ID: 11869633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for anaemia in human immunodeficiency virus/hepatitis C virus-coinfected patients treated with interferon plus ribavirin.
    Bani-Sadr F; Goderel I; Penalba C; Billaud E; Doll J; Welker Y; Cacoub P; Pol S; Perronne C; Carrat F;
    J Viral Hepat; 2007 Sep; 14(9):639-44. PubMed ID: 17697016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report.
    Zylberberg H; Benhamou Y; Lagneaux JL; Landau A; Chaix ML; Fontaine H; Bochet M; Poynard T; Katlama C; Pialoux G; Bréchot C; Pol S
    Gut; 2000 Nov; 47(5):694-7. PubMed ID: 11034587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection: results from Kyushu University Liver Disease Study.
    Ogawa E; Furusyo N; Kajiwara E; Takahashi K; Nomura H; Tanabe Y; Satoh T; Maruyama T; Nakamuta M; Kotoh K; Azuma K; Dohmen K; Shimoda S; Hayashi J;
    J Gastroenterol Hepatol; 2012 Jul; 27(7):1233-40. PubMed ID: 22098185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Re-treatment of previous non-responders and relapsers to interferon plus ribavirin with peginterferon alfa-2a (40KD), ribavirin ± amantadine in patients with chronic hepatitis C: randomized multicentre clinical trial.
    Pessôa MG; Cheinquer H; Almeida PR; Silva GF; Lima MP; Paraná R; Lacerda MA; Parise ER; Pernambuco JR; Pedrosa SS; Teixeira R; Sette H; Tatsch F
    Ann Hepatol; 2012; 11(1):52-61. PubMed ID: 22166561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial.
    Liu CH; Huang CF; Liu CJ; Dai CY; Liang CC; Huang JF; Hung PH; Tsai HB; Tsai MK; Chen SI; Lin JW; Yang SS; Su TH; Yang HC; Chen PJ; Chen DS; Chuang WL; Yu ML; Kao JH
    Ann Intern Med; 2013 Dec; 159(11):729-38. PubMed ID: 24297189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ribavirin with or without alpha interferon for chronic hepatitis C.
    Kjaergard LL; Krogsgaard K; Gluud C
    Cochrane Database Syst Rev; 2002; (2):CD002234. PubMed ID: 12076442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study.
    Samuel D; Bizollon T; Feray C; Roche B; Ahmed SN; Lemonnier C; Cohard M; Reynes M; Chevallier M; Ducerf C; Baulieux J; Geffner M; Albrecht JK; Bismuth H; Trepo C
    Gastroenterology; 2003 Mar; 124(3):642-50. PubMed ID: 12612903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effectiveness and complications of combination therapy with interferon alpha and ribavirin in patients with chronic hepatitis C].
    Hwang SY; Lee HJ; Park KT; Kim KY; Lee SM; Park CW; Kim TO; Kim GH; Heo J; Kang DH; Song GA; Cho M; Cho BM
    Korean J Gastroenterol; 2007 Mar; 49(3):166-72. PubMed ID: 18172345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients.
    Maddrey WC
    Semin Liver Dis; 1999; 19 Suppl 1():67-75. PubMed ID: 10349694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon-alpha plus ribavirin in chronic hepatitis C resistant to previous interferon-alpha course: results of a randomized multicenter trial.
    Andreone P; Gramenzi A; Cursaro C; Sbolli G; Fiorino S; Di Giammarino L; Miniero R; D'Errico A; Gasbarrini G; Bernardi M
    J Hepatol; 1999 May; 30(5):788-93. PubMed ID: 10365803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An open-safety study of dual antiviral therapy in real-world patients with chronic hepatitis C.
    Tinè F; Graviano D; Giannuoli G; Madonia S; Malizia G; Patti S; Fasola S; Cottone M; D'Amico G;
    Pharmacoepidemiol Drug Saf; 2010 Nov; 19(11):1113-23. PubMed ID: 20848397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C: a rapid and systematic review.
    Shepherd J; Waugh N; Hewitson P
    Health Technol Assess; 2000; 4(33):1-67. PubMed ID: 11134916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of peginterferon plus ribavirin in patients with chronic hepatitis C and bridging fibrosis or cirrhosis.
    Marrache F; Consigny Y; Ripault MP; Cazals-Hatem D; Martinot M; Boyer N; Degott C; Valla D; Marcellin P
    J Viral Hepat; 2005 Jul; 12(4):421-8. PubMed ID: 15985014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meta-analysis: combination therapy with interferon-alpha 2a/2b and ribavirin for patients with chronic hepatitis C previously non-responsive to interferon.
    San Miguel R; Guillén F; Cabasés JM; Buti M
    Aliment Pharmacol Ther; 2002 Sep; 16(9):1611-21. PubMed ID: 12197840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon-alpha-2b plus ribavirin: a review of its use in the management of chronic hepatitis C.
    Scott LJ; Perry CM
    Drugs; 2002; 62(3):507-56. PubMed ID: 11827565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined antiviral therapy of hepatitis C virus in dialysis patients: meta-analysis of clinical trials.
    Fabrizi F; Dixit V; Martin P; Messa P
    J Viral Hepat; 2011 Jul; 18(7):e263-9. PubMed ID: 21108701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.